Lung Cancer Therapeutics Market

Lung Cancer Therapeutics Market is expected to reach value of USD 30.5 Billion by 2030 at 9.11% CAGR during the forecast period 2022-2030.

Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, and fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the total lung cancers. The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four

Almost 85% of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.

The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. Notably, smoking is the primary driver for the rising cases of lung cancer. According to World Health Organization (WHO) tobacco kills more than 7 million people each year of which more than 6 million deaths are the result of direct tobacco use. Lung cancer is the leader with a whopping 37% of deaths. Of more concern is the rising rates of lung cancer due to passive smoking.

Other push factors such as, environmental pollution, rising cases of infections, growing rates of early detection and awareness, rising rates of fast growing lung cancer, and reimbursements and growing health insurance are also fuelling the growth of the market.

Key Players

F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer (US), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), and Sanofi (France) are some of the prominent players at the forefront of competition in the lung cancer market and are profiled in MRFR Analysis.

Segmentation by Type of Lung Cancer

1. Non-Small Cell Lung Cancer (NSCLC)
2. Small Cell Lung Cancer (SCLC)

The first and most fundamental segmentation of the lung cancer therapeutics market is based on the type of lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two primary categories. NSCLC accounts for approximately 85% of all lung cancer cases and can be further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. SCLC, while less common, is an aggressive and fast-growing form of lung cancer. Therapeutic approaches vary significantly between these two categories, highlighting the importance of this initial segmentation.

Segmentation by Treatment Modality

1. Surgery
2. Radiation Therapy
3. Chemotherapy
4. Targeted Therapy
5. Immunotherapy

The next crucial segmentation is based on the treatment modality employed to combat lung cancer. Each modality plays a unique role in the management and treatment of the disease. Surgery involves the removal of the tumor and affected tissue, while radiation therapy uses high-energy rays to target and destroy cancer cells. Chemotherapy utilizes drugs to kill cancer cells throughout the body, often as a systemic treatment. Targeted therapy focuses on specific molecular changes within cancer cells, while immunotherapy harnesses the body's immune system to fight cancer. The choice of treatment modality depends on the type and stage of the cancer, as well as the patient's overall health.

Segmentation by Stage

1. Stage I
2. Stage II
3. Stage III
4. Stage IV

The stage at which lung cancer is diagnosed significantly impacts treatment decisions. The segmentation based on cancer stage is essential, as it helps determine the extent of the disease and the appropriate therapeutic approach. Stage I and II are localized forms of the disease, with the cancer confined to the lung or nearby lymph nodes. In these early stages, surgery and localized treatments like radiation therapy are often the primary options. Stage III lung cancer has spread to the lymph nodes in the middle of the chest, requiring a more extensive treatment approach. Stage IV, the most advanced stage, indicates that the cancer has spread to distant organs. Treatment at this stage is often palliative, focusing on extending the patient's life and improving quality of life.

Segmentation by Geography

1. North America
2. Europe
3. Asia-Pacific
4. Latin America
5. Middle East and Africa

The prevalence and management of lung cancer can vary significantly based on geography. Therefore, segmentation by geographical regions is crucial in understanding market dynamics and patient needs. North America and Europe have well-established healthcare systems, leading to a higher prevalence of lung cancer cases and access to advanced therapeutics. In contrast, Asia-Pacific, Latin America, and the Middle East and Africa face unique challenges related to lung cancer therapeutics, including differences in healthcare infrastructure and regional variations in lung cancer subtypes.

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 646 845 9312

Email: sales@marketresearchfuture.com